CPAnet关于慢性肺曲霉病研究优先级的共识声明
慢性肺曲霉病(CPA)是一种高发病率和高死亡率的严重真菌感染,通常见于患有呼吸系统疾病的免疫功能正常患者。临床管理因流行病学、疾病动态、真菌学检测敏感性和特异性、抗真菌耐药机制及有效治疗管理策略的信息有限而受阻。慢性肺曲霉病网络(CPAnet)通过改良Delphi流程确定关键研究优先级,包括建立多国网络登记系统、验证不同诊断检测、建立经证实CPA患者样本的培养物收藏以及建立治疗结局定义的共识。
要点
- CPA多见于免疫功能正常但患有呼吸系统疾病者,临床表现非特异且常与基础病重叠。
- CPAnet通过改良Delphi流程确定研究优先级,旨在改善CPA患者管理与结局。
- 关键优先事项包括多国登记系统、诊断验证、培养物收藏及治疗结局定义共识。
核心结论
- CPA是一种被忽视且需关注的严重真菌感染,CPAnet共识确定了改善其诊疗的研究优先方向。
研究设计与样本
- CPAnet为自组织的多国研究协作,采用改良Delphi流程确定研究优先级。
主要发现
- CPA患者通常免疫功能正常但伴有呼吸系统疾病,临床表现非特异且与基础病影像学表现重叠。
- CPA临床管理受限于流行病学、疾病动态、真菌学检测性能、耐药机制及治疗管理策略的信息不足。
关键数值与推荐
- 关键研究优先级包括建立多国网络登记系统、验证不同诊断检测、建立经证实CPA患者样本的培养物收藏及建立治疗结局定义共识。
临床怎么用
- 临床应关注CPA在免疫功能正常呼吸疾病患者中的可能,并推动参与多国登记与诊断验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic pulmonary aspergillosis (CPA) is a severe fungal infection with a high morbidity and mortality, and is usually seen in immunocompetent patients with respiratory disorders. Clinical presentation is nonspecific and often overlaps with the symptoms and the radiological pattern caused by the underlying disease. Clinical management of CPA is further hampered by limited information about the epidemiology, disease dynamics, sensitivity and specificity of different mycological tests, mechanisms of antifungal resistance, efficient treatment and management strategies. In order to contribute to a better understanding and to improve CPA patient management and outcome, we established the Chronic Pulmonary Aspergillosis Network (CPAnet), a self-organized multinational research collaboration. Key research priorities, defined by using a modified Delphi process, include the establishment of a multinational web-based registry, the validation of different diagnostic tests, the establishment of a culture collection from samples of patients with proven CPA and the establishment of a consensus on a treatment outcome definition.
引用
- Godet C, Alastruey-Izquierdo A, Flick H, et al. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother. 2018. PMID: 29126309. doi:10.1093/jac/dkx390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。